团队拥有：

1.有一名专职副研究员负责实验室日常工作和技术指导、课题设计、项目实施、论文发表等工作。

2.临床有三名副主任医师负责管理48张病床和每月400名左右的出院患者。

3.目前科室还专门选派一名住院医师在美国开展博士后研究工作。

4.团队先后获批上海市肿瘤重点专科等荣誉。

基金与项目

1.        国家自然科学基金：81172022，KLF4调控uPAR在肝细胞癌发生上皮－间质转化中的作用和机制研究

课题负责人55万，2012.01-2015.12

2.        国家自然科学基金：81272917，FoxM1调控TGF-β1/Smad信号通路促进乳腺癌EMT机制研究。

课题负责人60万，2013.01-2016.12

3.        国家自然科学基金：81472576，KLF4通过HNF-6信号通路影响肝癌细胞分化的机制研究。

课题负责人72万，2015.01-2018.12

4.        国家自然科学基金：81772567，RNA编辑酶ADAR1调控PARP1在胃癌细胞化疗耐药中的作用及机制研究。

课题负责人55万，2018.01-2021.12

5.        国家自然科学基金：81972290，METTL14通过m6A修饰调控ADAR1促进结直肠癌发生和干性维持的机制研究。

课题负责人55万，2020.1-2023.12

6.        国家自然科学基金：82372706，METTL16/SENP3/LTF信号轴抑制铁死亡促进肝癌进展的作用和机制研究。

课题负责人49万，2024.01 - 2027.12

基金与项目

1. 国家自然科学基金：81172022，KLF4调控uPAR在肝细胞癌发生上皮－间质转化中的作用和机制研究

课题负责人55万，2012.01-2015.12

2. 国家自然科学基金：81272917，FoxM1调控TGF-β1/Smad信号通路促进乳腺癌EMT机制研究。

课题负责人60万，2013.01-2016.12

3. 国家自然科学基金：81472576，KLF4通过HNF-6信号通路影响肝癌细胞分化的机制研究。

课题负责人72万，2015.01-2018.12

4. 国家自然科学基金：81772567，RNA编辑酶ADAR1调控PARP1在胃癌细胞化疗耐药中的作用及机制研究。

课题负责人55万，2018.01-2021.12

5. 国家自然科学基金：81972290，METTL14通过m6A修饰调控ADAR1促进结直肠癌发生和干性维持的机制研究。

课题负责人55万，2020.1-2023.12

6. 国家自然科学基金：82372706，METTL16/SENP3/LTF信号轴抑制铁死亡促进肝癌进展的作用和机制研究。

课题负责人49万，2024.01 - 2027.12

7.浦东新区卫计委科技专项：PW2022E-02，基于PETCTC®单细胞测序指导下的CRC精准治疗临床研究。课题负责人100万，2022.12-2024.12

第一和通讯作者论文发表：

1.        Li Li , Shijun Yu , Ning Dou ,Xiao Wang , Yong Gao , Yandong Li. A new tandem repeat-enriched lncRNAXLOC_008672 promotes gastric carcinogenesis by regulating G3BP1 expression. CancerSci (IF: 4.966; Q1). 2024 Jun;115(6):1851-1865.

2.        Jialin Wang, Mengxi Xiu, JinWang, Yong Gao, Yandong Li. METTL16-SENP3-LTF axis confers ferroptosisresistance and facilitates tumorigenesis in hepatocellular carcinoma. J HematolOncol (IF: 11.059; Q1). 2024 Sep 2;17(1):78.

3.        Jiahua Yu, Shijun Yu, Jin Bai,Zhe Zhu, Yong Gao, Yandong Li. SDCBP modulates tumor microenvironment, tumorprogression and anti-PD1 efficacy in colorectal cancer. Cancer Gene Ther (IF:4.534; Q2). 2024 May;31(5):755-765.

4.        Li Li, Dacheng Xie, Shijun Yu,Muyuan Ma, Kailing Fan, Jingde Chen, Mengxi Xiu, Keping Xie, Yandong Li, andYong Gao. WNK1 Interaction with KEAP1 Promotes NRF2 Stabilization to Enhancethe Oxidative Stress Response in Hepatocellular Carcinoma. Cancer Res2024;84:2776–91

5.        Quan M, Chen Z, Chen J, Hai Y,Gao Y.Preliminary experience of oral fruquintinib-capecitabine as a newmaintenance treatment strategy for advanced colorectal cancer in the era ofcoronavirus disease 2019 (COVID-19): case report and literature review.J GastrointestOncol.2022 Oct;13(5):2660-2666. IF:2.1

6.        Zeng TM, Pan YF, Yuan ZG, ChenDS, Song YJ, Gao Y.Immune-related RNA signature predicts outcome of PD-1inhibitor-combined GEMCIS therapy in advanced intrahepaticcholangiocarcinoma.Front Immunol.2022 Sep 9;13:943066. IF:7.3

7.        Xiu M, Li L, Li Y, Gao Y. Anupdate regarding the role of WNK kinases in cancer.Cell Death Dis.2022 Sep19;13(9):795.IF: 9.0

8.        Wu Q, Hu Q, Hai Y, Li Y, Gao Y.METTL13 facilitates cell growth and metastasis in gastric cancer via aneEF1A/HN1L positive feedback circuit. J Cell Commun Signal.2023Mar;17(1):121-135.IF: 4.1

9.        Chong X, Chen J, Zheng N, ZhouZ, Hai Y, Chen S, Zhang Y, Yu Q, Yu S, Chen Z, Bao W, Quan M, Chen ZS, Zhan Y,Gao Y. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibitscolorectal cancer progression via upregulating PTEN. Mol Cancer. 2022 May26;21(1):118.IF: 37.3

10.    Li L, Yu S, Chen J, Quan M, GaoY, Li Y. miR-15a and miR-20b sensitize hepatocellular carcinoma cells tosorafenib through repressing CDC37L1 and consequent PPIA downregulation.CellDeath Discov. 2022 Jun 27;8(1):297.IF: 7.0

11.     Xiaodan Chong, Jingde Chen, Nanxin Zheng, Zhuqing Zhou, Yanan Hai,Shiqing Chen, Yu Zhang, Qingzhuo Yu, Shijun Yu, Zhiqin Chen, Wenfang Bao, MingQuan, Zhe-Sheng Chen, Yangyang Zhan, Yong Gao. PIK3CA mutations-mediateddownregulation of circLHFPL2 inhibits colorectal cancer progression viaupregulating PTEN. Mol Cancer. 2022 May 26;21(1):118(IF=27.4)

12.     Zhiqin Chen, Jinde Chen, Yong Gao, Ming Quan. Heterogeneous clinicaland pathological landscapes of HER2 positive colorectal cancer. Expert RevAnticancer Ther. 2021 Oct;21(10):1097-1104.(IF=4.51)

13.     Zhiqin Chen, Haifei Song, Xiaochen Zeng, Ming Quan, Yong Gao.Screening and discrimination of optimal prognostic genes for pancreatic cancerbased on a prognostic prediction model. G3 (Bethesda). 2021 Oct 19;11(11).(IF=3.15)

14.     Shijun Yu, Qingqing Hu, Kailing Fan, Chen Yang, Yong Gao. CSNK2Bcontributes to colorectal cancer cell proliferation by activating the mTORsignaling. J Cell Commun Signal. 2021 Sep;15(3):383-392.(IF=5.78)

15.     Yu S, Li L, Fan K, Li Y, Gao Y. A Genome-Scale CRISPRKnock-Out Screen Identifies MicroRNA-5197-5p as a Promising RadiosensitiveBiomarker in Colorectal Cancer.Front Oncol.2021 Jul 30;11:696713.IF:6.244

16.     Chen Z, Chen J, Gao Y, Quan M. Heterogeneous clinical andpathological landscapes of HER2 positive colorectal cancer.Expert RevAnticancer Ther. 2021 Jul 14;1-8.IF:4.513

17.     Liu X, Zhou P, He K, Wen Z, Gao Y. Dioscorea Zingiberensis NewSaponin Inhibits the Growth of Hepatocellular Carcinoma by Suppressing theExpression of Long Non-coding RNA TCONS-00026762.Front Pharmacol. 2021 May3;12:678620.IF:5.81

18.     Li L, Tao X, Li Y, Gao Y, Li Q. CDC37L1 acts as a suppressor ofmigration and proliferation in gastric cancer by down-regulating CDK6. JCancer.2021 Mar 31;12(11):3145-3153.IF:4.2

19.     Yu S, Hu Q, Fan K, Yang C, Gao Y. CSNK2B contributes to colorectalcancer cell proliferation by activating the mTOR signaling.J Cell CommunSignal.2021 Sep;15(3):383-392.IF:5.78

20.     Wang X, Dou N, Wang J, Zhang Y, Li Y, Gao Y.FOXM1-induced miR-552expression contributes to pancreatic cancer progression by targeting multipletumor suppressor genes.Int J Biol Sci.2021 Mar 1;17(4):915-925.IF:6.584

21.     Yu S, Li L, Cai H, He B, Gao Y, Li Y. Overexpression of NELFEcontributes to gastric cancer progression via Wnt/β-catenin signaling-mediatedactivation of CSNK2B expression.J Exp Clin Cancer Res.2021 Feb1;40(1):54.IF:11.16

22.     Xie D, Yu S, Li L, Quan M, Gao Y. The FOXM1/ATX signalingcontributes to pancreatic cancer development..Am J Transl Res. 2020 Aug15;12(8):4478-4487. eCollection 2020.IF:4.063

23.     Dou N, Hu Q, Li L, Wu Q, Li Y, Gao Y.USP32 promotes tumorigenesisand chemoresistance in gastric carcinoma via upregulation of SMAD2.Int J BiolSci. 2020 Mar 12;16(9):1648-1657.IF:6.58

24.     Shijun Yu, Jingde Chen, Ming Quan, Li Li, Yandong Li, Yong Gao. CD63negatively regulates hepatocellular carcinoma development through suppressionof inflammatory cytokine-induced STAT3 activation.J Cell Mol Med. 2020 Dec4;25(2):1024-1034.IF:5.31

25.     Chen J, Quan M, Chen Z, Zeng T, Li Y, Zhou Y, Hai Y, GaoY.Camrelizumab in advanced or metastatic solid tumour patients with DNAmismatch repair deficient or microsatellite instability high: an open-labelprospective pivotal trial. J Cancer Res Clin Oncol. 2020 Oct;146(10):2651-2657IF:3.656

26.     Yandong Li, Shijun Yu, Li Li, Jingde Chen, Ming Quan, Qinchuan Li,Yong Gao.KLF4-mediated upregulation of CD9 and CD81 suppresses hepatocellularcarcinoma development via JNK signaling.Cell Death Dis. 2020 Apr29;11(4):299.IF:8.464

27.     Zhou C, Wei Z, Zhang Z, Zhang B, Zhu C, Chen K, Chuai G, Qu S, XieL, Gao Y, Liu Q. pTuneos: prioritizing tumor neoantigens from next-generationsequencing data.Genome Med. 2019 Oct 30;11(1):67.IF:11.11

28.     Li Li, Shijun Yu, Qiong Wu, Ning Dou, Yandong Li, Yong Gao.KLF4-Mediated CDH3 Upregulation Suppresses Human Hepatoma Cell Growth andMigration via GSK-3β Signaling. Int J Biol Sci. 2019 Mar10;15(5):953-961.IF:4.858

29.     Yu S, Gautam N, Quan M, Gao Y. RSRC1 suppresses gastric cancer cellproliferation and migration by regulating PTEN expression. Mol Med Rep. 2019 Aug;20(2):1747-1753. IF：2.1

30.     Li Y, Yu S, Wang X, Ye X, He B, Quan M, Gao Y. SRPK1facilitates tumor cell growth via modulating the small nucleolar RNA expressionin gastric cancer. J Cell Physiol. 2019 Aug;234(8):13582-13591. IF：5.546

31.     Yu S, Wang X, Dou N, Zhou J, Gao Y, Li Y. B-celllymphoma-2-associated transcription factor 1 is overexpressed and contributesto sorafenib resistance in hepatocellular carcinoma. Hepatol Res. 2019Nov;49(11):1329-1340 IF：3.165

32.     Li L, Yu S, Wu Q, Dou N, Li Y, Gao Y. KLF4-Mediated CDH3Upregulation Suppresses Human Hepatoma Cell Growth and Migration via GSK-3βSignaling. Int J Biol Sci. 2019;15(5):953-961. IF：4.858

33.    Chen J, Li L, Zhou Z, Yu S, LiY, Gao Y. FAPP2 promotes tumor cell growth in human colon cancer throughactivation of Wnt signaling. Exp Cell Res. 2019 Jan 1;374(1):12-18. IF：3.383

34.     Dou N, Yang D, Yu S, Wu B, Gao Y, Li Y. SNRPA enhances tumourcell growth in gastric cancer through modulating NGF expression.Cell Prolif. 2018 Oct;51(5):e12484. IF：5.753

35.     Yu S, Li L, Wu Q, Dou N, Li Y, Gao Y. PPP2R2D, a regulatorysubunit of protein phosphatase 2A, promotes gastric cancer growth andmetastasis via mechanistic target of rapamycin activation. Int J Oncol. 2018Jun;52(6):2011-2020. IF：3.899

36.     Zhang Y, Ye X, Chen L, Wu Q, Gao Y, Li Y. PARI functions as a newtranscriptional target of FOXM1 involved in gastric cancer development. Int JBiol Sci. 2018;14(5):531-541. IF：4.858

37.     Wu Q, Yu S, Chen J, Li Y, Gao Y. Downregulation of STRAPpromotes tumor growth and metastasis in hepatocellular carcinoma via reducingPTEN level. IUBMB Life. 2018 Feb;70(2):120-128. IF：3.244

38.     Wang Y, Jiang J, Li Q, Ma H, Xu Z, Gao Y. KAP1 is overexpressed inhepatocellular carcinoma and its clinical significance. Int J Clin Oncol. 2016Oct;21(5):927-933. doi: 10.1007/s10147-016-0979-8. Epub 2016 Apr 19. PubMedPMID: 27095111.

39.     Wang X, He B, Gao Y, Li Y. FOXR2 contributes to cell proliferationand malignancy in human hepatocellular carcinoma. Tumour Biol. 2016Aug;37(8):10459-67. doi: 10.1007/s13277-016-4923-3. Epub 2016 Feb 5. PubMedPMID: 26846213.

40.     Ye X, Zhang Y, Wang X, Li Y, Gao Y. Tumor-suppressive functions oflong-chain acyl-CoA synthetase 4 in gastric cancer. IUBMB Life. 2016Apr;68(4):320-7. doi: 10.1002/iub.1486. Epub 2016 Mar 7. PubMed PMID: 26949059.

41.     Li Y, Wang X, He B, Cai H, Gao Y. Downregulation andtumor-suppressive role of XPO5 in hepatocellular carcinoma. Mol Cell Biochem.2016 Apr;415(1-2):197-205. doi: 10.1007/s11010-016-2692-3. Epub 2016 Mar 21.PubMed PMID: 27000860.

42.     Li Q, Li Y, Wang Y, Cui Z, Gong L, Qu Z, Zhong Y, Zhou J, Zhou Y,Gao Y, Li Y. Quantitative proteomic study of human prostate cancer cells withdifferent metastatic potentials. Int J Oncol. 2016 Apr;48(4):1437-46. doi:10.3892/ijo.2016.3378. Epub 2016 Feb 4. PubMed PMID: 26846621.

43.     Ye X, Zhang Y, He B, Meng Y, Li Y, Gao Y. Quantitative proteomicanalysis identifies new effectors of FOXM1 involved in breast cancer cellmigration. Int J Clin Exp Pathol. 2015;8(12):15836-44. eCollection 2015. PubMedPMID: 26884854; PubMed Central PMCID: PMC4730067.

44.     Li Y, Lin Y, Li Q, Gao Y. SRrp35 suppresses cell proliferation andmalignancy in hepatocellular carcinoma. Hepatol Res. 2015 Dec;45(12):1241-7.doi: 10.1111/hepr.12493. Epub 2015 Mar 17. PubMed PMID: 25594558.

45.     Chen Y, Cha Z, Fang W, Qian B, Yu W, Li W, Yu G, Gao Y. Theprognostic potential and oncogenic effects of PRR11 expression in hilarcholangiocarcinoma. Oncotarget. 2015 Aug 21;6(24):20419-33. doi:10.18632/oncotarget.3983. PubMed PMID: 25971332; PubMed Central PMCID:PMC4653015.

46.     Feng C, Li X, Dong C, Zhang X, Zhang X, Gao Y. RGD-modifiedliposomes enhance efficiency of aclacinomycin A delivery: evaluation of theireffect in lung cancer. Drug Des Devel Ther. 2015;9:4613-20. doi:10.2147/DDDT.S85993. eCollection 2015. PubMed PMID: 26316700; PubMed CentralPMCID: PMC4541546.

47.     Cai H, Chen J, He B, Li Q, Li Y, Gao Y. A FOXM1 related longnon-coding RNA contributes to gastric cancer cell migration. Mol Cell Biochem.2015 Aug;406(1-2):31-41. doi: 10.1007/s11010-015-2421-3. Epub 2015 Apr 24.PubMed PMID: 25907137.

48.     Cai H, Ye X, He B, Li Q, Li Y, Gao Y. LncRNA-AP001631.9 promotescell migration in gastric cancer. Int J Clin Exp Pathol. 2015;8(6):6235-44.eCollection 2015. PubMed PMID: 26261500; PubMed Central PMCID: PMC4525834.

49.     Chen J, Jiang H, Wu Y, Li Y, Gao Y. A novel glycyrrhetinicacid-modified oxaliplatin liposome for liver-targeting and in vitro/vivoevaluation. Drug Des Devel Ther. 2015;9:2265-75. doi: 10.2147/DDDT.S81722.eCollection 2015. PubMed PMID: 25945038; PubMed Central PMCID: PMC4408971.

50.     Wang Y, Wang Q, Zhang N, Ma H, Gu Y, Tang H, Xu Z, Gao Y.Identification of microRNAs as novel biomarkers for detecting esophagealsquamous cell carcinoma in Asians: a meta-analysis. Tumour Biol. 2014Nov;35(11):11595-604. doi: 10.1007/s13277-014-2350-x. Epub 2014 Aug 19. PubMedPMID: 25135426.

51.     Shi M, Cui J, Du J, Wei D, Jia Z, Zhang J, Zhu Z, Gao Y, Xie K. Anovel KLF4/LDHA signaling pathway regulates aerobic glycolysis in andprogression of pancreatic cancer. Clin Cancer Res. 2014 Aug 15;20(16):4370-80.doi: 10.1158/1078-0432.CCR-14-0186. Epub 2014 Jun 19. PubMed PMID: 24947925;PubMed Central PMCID: PMC4134726.

52.     Li Q, Tian Y, Li D, Sun J, Shi D, Fang L, Gao Y, Liu H. The effectof lipocisplatin on cisplatin efficacy and nephrotoxicity in malignant breastcancer treatment. Biomaterials. 2014 Aug;35(24):6462-72. doi:10.1016/j.biomaterials.2014.04.023. Epub 2014 May 3. PubMed PMID: 24797881.

53.     Li Q, Wang H, Yu L, Zhou J, Chen J, Zhang X, Chen L, Gao Y, Li Q.ChIP-seq predicted estrogen receptor biding sites in human breast cancer cellline MCF7. Tumour Biol. 2014 May;35(5):4779-84. doi: 10.1007/s13277-014-1627-4.Epub 2014 Jan 28. PubMed PMID: 24470138.

54.     Yang L, Yang S, Liu J, Wang X, Ji J, Cao Y, Lu K, Wang J, Gao Y.Expression of GRP78 predicts taxane-based therapeutic resistance and recurrenceof human gastric cancer. Exp Mol Pathol. 2014 Apr;96(2):235-41. doi:10.1016/j.yexmp.2014.02.011. Epub 2014 Mar 3. PubMed PMID: 24602846.

55.     Huang C, Xie D, Cui J, Li Q, Gao Y, Xie K. FOXM1c promotespancreatic cancer epithelial-to-mesenchymal transition and metastasis viaupregulation of expression of the urokinase plasminogen activator system. ClinCancer Res. 2014 Mar 15;20(6):1477-88. doi: 10.1158/1078-0432.CCR-13-2311. Epub2014 Jan 22. PubMed PMID: 24452790; PubMed Central PMCID: PMC3959252.

56.     Luo JH, Zhou J, Gao Y. Correlation between periostin and SNCG andesophageal cancer invasion, infiltration and apoptosis. Asian Pac J Trop Med.2013 Jul;6(7):516-9. doi: 10.1016/S1995-7645(13)60088-7. PubMed PMID: 23768821.

57.     Jiang H, Lin Y, Yang CQ, Li Q, Luo J, Zhou Y, Xue J, Wei W, Gao Y.Quantitative assessment of the association between XRCC6 C1310G polymorphismand cancer risk. Tumour Biol. 2013 Apr;34(2):779-85. doi:10.1007/s13277-012-0607-9. Epub 2012 Dec 28. PubMed PMID: 23271361.

58.     Li Q, Gao Y, Xu ZG, Jiang H, Yu YY, Zhu ZG. Effect of antisenseoligodeoxynucleotide targeted against NF-κB/P65 on cell proliferation andtumorigenesis of gastric cancer. Clin Exp Med. 2013 Feb;13(1):11-9. doi:10.1007/s10238-011-0174-1. Epub 2012 Jan 11. PubMed PMID: 22234797.

59.     Li Q, Gao Y, Jia Z, Mishra L, Guo K, Li Z, Le X, Wei D, Huang S, XieK. Dysregulated Krüppel-like factor 4 and vitamin D receptor signalingcontribute to progression of hepatocellular carcinoma. Gastroenterology. 2012Sep;143(3):799-810.e2. doi: 10.1053/j.gastro.2012.05.043. Epub 2012 Jun 4.PubMed PMID: 22677193; PubMed Central PMCID: PMC3653768.

60.     Jiang H, Zhang X, Luo J, Dong C, Xue J, Wei W, Chen J, Zhou J, GaoY, Yang C. Knockdown of hMex-3A by small RNA interference suppresses cellproliferation and migration in human gastric cancer cells. Mol Med Rep. 2012Sep;6(3):575-80. doi: 10.3892/mmr.2012.943. Epub 2012 Jun 11. PubMed PMID:22692246.

61.     Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D, Le X, Suyun H, Huang S,Wang L, Xie K. Combining betulinic acid and mithramycin a effectivelysuppresses pancreatic cancer by inhibiting proliferation, invasion, andangiogenesis. Cancer Res. 2011 Aug 1;71(15):5182-93. doi:10.1158/0008-5472.CAN-10-2016. Epub 2011 Jun 14. PubMed PMID: 21673052; PubMedCentral PMCID: PMC3245664.